Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Burcu Yigit

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Clinical Immunology (Orlando, Fla.)|July 3, 2016
Slamf6 negatively regulates autoimmunityNinghai Wang, Marton Keszei, Peter Halibozek, et al.
Frontiers in Immunology|May 6, 2014
SAP-Dependent and -Independent Regulation of Innate T Cell Development Involving SLAMF ReceptorsJaime De Calisto, Ninghai Wang, Guoxing Wang, et al.
Immunology Letters|June 29, 2013
SAP modulates B cell functions in a genetic background-dependent mannerCynthia Detre, Burcu Yigit, Marton Keszei, et al.
Frontiers in Immunology|May 1, 2015
Negative Regulation of Humoral Immunity Due to Interplay between the SLAMF1, SLAMF5, and SLAMF6 ReceptorsNinghai Wang, Peter J Halibozek, Burcu Yigit, et al.
Frontiers in Immunology|May 7, 2019
The Checkpoint Regulator SLAMF3 Preferentially Prevents Expansion of Auto-Reactive B Cells Generated by Graft-vs.-Host DiseaseNinghai Wang, Burcu Yigit, Cees E van der Poel, et al.
Plos One|March 24, 2015
Migration of myeloid cells during inflammation is differentially regulated by the cell surface receptors Slamf1 and Slamf8Guoxing Wang, Boaz J van Driel, Gongxian Liao, et al.
Oncotarget|March 31, 2016
A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cellsBurcu Yigit, Peter J Halibozek, Shih-Shih Chen, et al.
Cancer Immunology Research|July 19, 2019
SLAMF6 as a Regulator of Exhausted CD8<sup>+</sup> T Cells in CancerBurcu Yigit, Ninghai Wang, Elisa Ten Hacken, et al.
Nature Metabolism|August 20, 2019
Increased β-cell proliferation before immune cell invasion prevents progression of type 1 diabetesErcument Dirice, Sevim Kahraman, Dario F De Jesus, et al.
Nature Communications|February 6, 2024
A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndromeTerese C Hammond, Marco A Purbhoo, Sapana Kadel, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Clinical Immunology (Orlando, Fla.)|July 3, 2016
Slamf6 negatively regulates autoimmunityNinghai Wang, Marton Keszei, Peter Halibozek, et al.
Frontiers in Immunology|May 6, 2014
SAP-Dependent and -Independent Regulation of Innate T Cell Development Involving SLAMF ReceptorsJaime De Calisto, Ninghai Wang, Guoxing Wang, et al.
Immunology Letters|June 29, 2013
SAP modulates B cell functions in a genetic background-dependent mannerCynthia Detre, Burcu Yigit, Marton Keszei, et al.
Frontiers in Immunology|May 1, 2015
Negative Regulation of Humoral Immunity Due to Interplay between the SLAMF1, SLAMF5, and SLAMF6 ReceptorsNinghai Wang, Peter J Halibozek, Burcu Yigit, et al.
Frontiers in Immunology|May 7, 2019
The Checkpoint Regulator SLAMF3 Preferentially Prevents Expansion of Auto-Reactive B Cells Generated by Graft-vs.-Host DiseaseNinghai Wang, Burcu Yigit, Cees E van der Poel, et al.
Plos One|March 24, 2015
Migration of myeloid cells during inflammation is differentially regulated by the cell surface receptors Slamf1 and Slamf8Guoxing Wang, Boaz J van Driel, Gongxian Liao, et al.
Oncotarget|March 31, 2016
A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cellsBurcu Yigit, Peter J Halibozek, Shih-Shih Chen, et al.
Cancer Immunology Research|July 19, 2019
SLAMF6 as a Regulator of Exhausted CD8<sup>+</sup> T Cells in CancerBurcu Yigit, Ninghai Wang, Elisa Ten Hacken, et al.
Nature Metabolism|August 20, 2019
Increased β-cell proliferation before immune cell invasion prevents progression of type 1 diabetesErcument Dirice, Sevim Kahraman, Dario F De Jesus, et al.
Nature Communications|February 6, 2024
A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndromeTerese C Hammond, Marco A Purbhoo, Sapana Kadel, et al.
Pageof 1